Recently, Sanofi announced that the marketing application for dupilumab injection (trade name: Dupixent) has been approved by the National Medical Products Administration (NMPA) of China for the treatment of adult patients with moderate to severe prurigo nodularis.Becomes the first and only innovative drug approved in China for the treatment of moderate to severe prurigo nodularis.。According to Sanofi's semi-annual report, the sales of this product reached a new high again this year.Global sales reached 4.878 billion euros (approximately 5.366 billion US dollars) in half a year, with annual sales expected to exceed 10 billion euros.In addition,DegreeDupilumab was included in China's medical insurance catalog in 2020, and with the continuous expansion of its indications, the domestic market size is expected to increase further.
Previously, Dupilumab was approved in China for patients aged 6 months and above, covering the entire age range from infancy to adulthood.The approval of nodular prurigo marks another significant breakthrough for Dupixent in the field of Type 2 inflammation, following its use for moderate-to-severe atopic dermatitis.
The treatment demand for nodular prurigo is increasing year by year.
The Number of Patients in China Exceeds 600,000Prurigo Nodularis: A Chronic Inflammatory Skin ConditionPrurigo nodularis is a chronic inflammatory skin disease characterized by intensely itchy, symmetrically distributed nodules. These nodules are typically located on the extensor surfaces of the limbs but can also affect parts of the trunk. When patients are unable to reach the central back area, a characteristic "butterfly sign" may appear. This skin condition significantly and negatively impacts patients' quality of life, affecting mental health, daily activities, and social interactions. The disease primarily affects middle-aged and elderly individuals, as well as those with atopic dermatitis, type 2 diabetes, thyroid disorders, hepatitis C virus infection, hepatic and renal insufficiency, non-Hodgkin lymphoma, and mental health conditions—especially depression and anxiety—making them more susceptible to developing prurigo nodularis.Prurigo Nodularis is aRequire Long-Term ManagementChronic diseases,CurrentlyThere is no radical cure.According to statistics,From 2016 to 2020, the number of patients with prurigo nodularis in China increased from 554,000 to 593,000, showing a gradual upward trend, with an average annual growth rate of 1.7% during this period.。It is predicted that by 2025 and 2030, the number of patients will further increase to 633,000 and 666,000, with average annual growth rates of 1.3% and 1.0%, respectively.Relevant data shows that the market size for prurigo nodularis treatment drugs in China is expanding year by year. With the increase in the number of patients, and the entry of innovative topical and oral medications into the prurigo nodularis treatment market in the future, this market is expected to continue growing.It is expected that by 2030, the market size will reach 1.67 billion yuan, with a compound annual growth rate of 3.40%.Market Size and Forecast for Treatment Drugs of Prurigo NodularisDerived from public information,Compiled by Zhongkang Industry Research InstituteDupilumab Has Huge Market Potential
Hospital sales growth rate 193.2%, retail sales growth rate 324.9%
Dupilumab is an anti-IL-4/IL-13 monoclonal antibody jointly developed by Sanofi and Regeneron. It selectively inhibits key signaling mediated by IL-4 and IL-13, thereby interrupting the Th2 inflammatory pathway and reducing abnormal physiological responses caused by Th2 inflammation., for the treatment of diseases associated with Th2-type inflammationIn 2017, dupilumab was first approved by the FDA for the treatment of adult patients with moderate-to-severe atopic dermatitis. Currently, dupilumab has received multiple approvals for uses including the treatment of moderate-to-severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, as well as asthma and atopic dermatitis in specific age groups.。Dupilumab was approved in China in June 2020 for the treatment of adult patients with moderate to severe atopic dermatitis, and was included in the national medical insurance at the end of December of the same year.Becoming the only targeted biologic in this version of the medical insurance directory for the treatment of moderate to severe atopic dermatitis. This approval means that it can be used to treat patients with moderate to severe atopic dermatitis who are unresponsive, contraindicated, or intolerant to conventional therapies, providing a new treatment option and assurance for this patient population.Subsequently, in September 2021, the indication for dupilumab was expanded to include patients aged 12 years and older with moderate-to-severe atopic dermatitis. In February 2022, the eligible population for the drug was further extended to include children aged 6 to 11 years with moderate-to-severe atopic dermatitis. Thus far,Dupilumab becomes the first targeted biologic in China approved for treating moderate-to-severe atopic dermatitis across all age groups (from infancy to adulthood).。The expansion of the indications scope increases the patient audience, and sales rise accordingly.According to the data from the CKDMC systemFrom 2020 to 2022, the sales of Dupilumab in China increased year by year.In 2022, the sales of Dupilumab in tiered hospitals reached 1.035 billion yuan, increasing by 193.2% compared to 2021; in the retail market, the sales exceeded 250 million yuan in 2022, with a growth rate as high as 324.9%. In the first half of 2023, the sales of Dupilumab in tiered hospitals reached 851 million yuan, and the sales in retail pharmacies were 220 million yuan.Sales of Dupilumab in China (2020-2022)Source: CKDM System,整理by Sino Health Industry Research InstituteThe newly approved indication for nodular prurigo will further expand the audience for dupilumab, and the market size is expected to grow even larger.Besides,Dupilumab has other indications such asSinusitis,COPD and others are undergoing clinical trials, fully showcasing the future market potential of Dupilumab.。 Part of Dupilumab's Indications Under Research in ChinaSource: Public data, organized by Sino Health Industry Research InstituteNew IndicationThe approval is a major breakthrough,The treatment needs for this chronic inflammatory skin disease are urgent, and Dupilumab offers hope to patients.. WithIn ChinaThe increasing number of patients with nodular prurigo makes the prospect of this market very promising. Moreover,Dupilumab's clinical trials in other fields also show potential market opportunities, creating more possibilities for future growth.。Continuously expanding the range of indications and constantly improving disease treatment methods, Dupilumab provides more treatment options and brings new hope to the medical field. In the future, it is expected that Dupilumab will bring health and well-being to more patients.
